A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Type 2 Diabetes With Chronic Kidney Disease

Interventions

DRUG: Elecoglipron
DRUG: Placebo

Sponsor

AstraZeneca